Abilify Maintena, an atypical antipsychotic, is an intramuscular depot formulation of aripiprazole. It is a sterile lyophilized powder that, when reconstituted with sterile water for injection, forms ...
Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...
On Monday, May 7, during a poster session at the 2018 Annual Meeting of the American Psychiatric Association, researchers presented new data on the injectable antipsychotic treatment aripiprazole ...
Abilify Asimtufii (aripiprazole) is prescribed to help treat schizophrenia and bipolar I disorder. The drug comes as a suspension (a liquid mixture) that a healthcare professional injects into a ...
PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...
Aristada (aripiprazole lauroxil) is a prescription drug that’s used to treat schizophrenia. Aristada is given by a healthcare professional as an injection into a muscle. Aristada is used as a ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...
ABILIFY extended–release injectable suspension, for intramuscular use, is administered to the patient just once every four weeks. It first became available to patients in the US in March 2013 and is ...
Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...
TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) ...
In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results